drugset / Trial / NCT00729742
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).
Timeline
- Start
- 2009-02
- Primary completion
- 2010-06
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | dalotuzumab | Monoclonal antibody | 10 mg/kg | Intravenous |